NewsRx

Search our medical news database

Herpes Simplex Virus

HSV-1 tegument protein fusion confers enhanced bystander and therapeutic effects

Published in Health and Medicine Week, March 13th, 2006

According to recent research from the United States, the fusion of the herpes simplex virus-1 (HSV-1) tegument protein vp22 to cytosine deaminase (CD) confers enhanced bystander effect and increased therapeutic benefit.

"A major limitation in cancer gene therapy, specifically gene-dependent enzyme prodrug therapy (GDEPT), is inefficient gene delivery and expression. The suicide gene CD and its substrate, 5-fluorocytosine (5-FC), have been extensively explored due to the inherent bystander effect achieved through diffusion of the toxic metabolite 5-fluorouracil (5-FU)."

"In this study," wrote K.C. Lee and colleagues, University of Michigan, "we aimed...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook